Zentalis Pharmaceuticals (ZNTL) Shares Outstanding (2019 - 2026)

Zentalis Pharmaceuticals has reported Shares Outstanding for 8 years, with the latest figure at $71.2 million in Q1 2026.

• For the quarter ending Q1 2026, Shares Outstanding fell 1.1% year-over-year to $71.2 million; the trailing twelve-month figure through Mar 2026 stood at $71.2 million (down 1.1% YoY), and the FY2025 full-year result was $69.1 million, down 3.08% from the prior year.
• Shares Outstanding for Q1 2026 stood at $71.2 million, up from $69.1 million in the prior quarter.
• The five-year high for Shares Outstanding was $72.2 million in Q3 2025, with the low at $45.6 million in Q1 2022.
• Average Shares Outstanding over 5 years is $66.6 million, with a median of $70.8 million recorded in 2023.
• Year-over-year, Shares Outstanding surged 37.88% in 2022 and dropped 3.08% in 2025.
• Tracing ZNTL's Shares Outstanding over 5 years: stood at $59.3 million in 2022, then advanced by 19.38% to $70.8 million in 2023, then grew by 0.73% to $71.3 million in 2024, then slipped by 3.08% to $69.1 million in 2025, then rose by 3.0% to $71.2 million in 2026.
• The last three Shares Outstanding figures came in at $71.2 million (Q1 2026), $69.1 million (Q4 2025), and $72.2 million (Q3 2025), per Business Quant data.

Peer Comparison